Skip to main content

Advertisement

Log in

Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807

    Article  CAS  PubMed  Google Scholar 

  2. Quintás-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15):3109–3117

    Article  PubMed Central  PubMed  Google Scholar 

  3. Duong VH, Komrokji RS (2014) The role of pacritinib in the management of myelofibrosis. Expert Rev Hematol 7(3):325–332

    Article  CAS  PubMed  Google Scholar 

  4. Verstovsek S, Mesa RA, Salama MA et al (2013) Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia Vera (PV), and essential thrombocythemia (ET). Blood 122:665

    Google Scholar 

  5. Barosi G, Mesa R, Finazzi G et al (2013) Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121(23):4778–4781

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Zhou T, Georgeon S, Moser R et al (2014) Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia 28(2):404–407

    Article  CAS  PubMed  Google Scholar 

  7. Heine A, Held SAE, Daeke SN et al (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122(7):1192–1202

    Article  CAS  PubMed  Google Scholar 

  8. Besancenot R, Roos-Weil D, Tonetti C et al (2014) JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood 124(13):2104–2115

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Tiedt R, Coers J, Ziegler S et al (2009) Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood 113(8):1768–1777

    Article  CAS  PubMed  Google Scholar 

  10. Ng AP, Kauppi M, Metcalf D et al (2014) Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci U S A 111(16):5884–5889

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported by BolognAIL, ELN, AIRC, progetto Regione-Università 2010–2012, FP7, NGS-PTL Project.

Conflict of interest

The authors declare that they have no competing interests.

Authorship

All authors wrote the paper and gave final approval to the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. Catani.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polverelli, N., Catani, L., Vianelli, N. et al. Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms. Ann Hematol 94, 1585–1587 (2015). https://doi.org/10.1007/s00277-015-2397-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2397-9

Keywords

Navigation